Figure 5

(a) Effect of olmesartan on cardiac function in the PO heart. The ejection fraction was measured in the sham-operated and PO hearts (n=6 in each group) after 28 days of aortic constriction (sham, sham heart; S, saline; H, hydralazine; O, olmesartan). Note that systolic function was preserved in the olmesartan group after 28 days of constriction, in contrast to the saline- and hydralazine-treated hearts. (b) Effect of olmesartan on cardiac function in the CTGF- and TGF-β1-infused hearts. After 14 days of continuous administration of growth factors, cardiac function was reduced in the nontreated rats (control), and olmesartan treatment (olmesartan) ameliorated this cardiac dysfunction.